ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD 3.125
-0.040 (-1.26%)
Oct 9, 2026, 4:08 PM HKT
HKG:1541 Revenue
ImmuneOnco Biopharmaceuticals (Shanghai) had revenue of 37.25M CNY in the half year ending June 30, 2026, with 5,080.39% growth. This brings the company's revenue in the last twelve months to 147.53M, up 25.61% year-over-year. In the year 2025, ImmuneOnco Biopharmaceuticals (Shanghai) had annual revenue of 154.29M with 108.09% growth. That makes ImmuneOnco Biopharmaceuticals (Shanghai) the 33,288th largest company in the world by revenue and 2,006th in Hong Kong.
Revenue (ttm)
147.53M CNY
Revenue Growth
+25.61%
P/S Ratio
7.88
Revenue / Employee
748.87K CNY
Employees
197
Market Cap
1.34B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.29M | 80.15M | 108.09% |
| Dec 31, 2024 | 74.15M | 66.45M | 863.60% |
| Dec 31, 2023 | 7.70M | 2.01M | 35.24% |
| Dec 31, 2022 | 5.69M | -8.12M | -58.79% |
| Dec 31, 2021 | 13.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.50B |
| JW (Cayman) Therapeutics Co. | 333.25M |
| Guangzhou Innogen Pharmaceutical Group | 176.96M |
| CANbridge Pharmaceuticals | 64.28M |
| Beijing Biostar Pharmaceuticals | 63.74M |
| Zhaoke Ophthalmology | 40.41M |
| SinoMab BioScience | 6.28M |
| Cloudbreak Pharma | 2.11M |